Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» AstraZeneca Announces Phase III Results for Lesinurad in Combination with Febuxostat in Tophaceous Gout Patients at European League Against Rheumatism Annual Congress (EULAR 2015)
AstraZeneca Announces Phase III Results for Lesinurad in Combination with Febuxostat in Tophaceous Gout Patients at European League Against Rheumatism Annual Congress (EULAR 2015)
AstraZeneca Announces Phase III Results for Lesinurad in Combination with Febuxostat in Tophaceous Gout Patients at European League Against Rheumatism Annual Congress (EULAR 2015)
Submitted by
admin
on June 14, 2015 - 10:50pm
Source:
Yahoo
News Tags:
AstraZeneca
lesinurad
febuxostat
tophaceous gout
Headline:
AstraZeneca Announces Phase III Results for Lesinurad in Combination with Febuxostat in Tophaceous Gout Patients at European League Against Rheumatism Annual Congress (EULAR 2015)
Do Not Allow Advertisers to Use My Personal information
